A Review of Research Conducted with Probiotic E. coli Marketed as Symbioflor
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
This review article summarizes the scientific literature that is currently available about a probiotic E. coli that is known under the name Symbioflor E. coli. The probiotic is marketed for human use and has been subjected to over 20 years of scientific research. As is presented here, the available literature not only contains multiple works to investigate and analyse the probiotic activity of this E. coli, but also describes a variety of other research experiments, dealing with a surprising and interesting range of subjects. By compiling all these works into one review article, more insights into this interesting probiotic E. coli were obtained.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Escherichia coli Nissle 1917 (EcN) has been used as a probiotic since its isolation over 100 years ago21.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bacteriocins—A viable alternative to antibiotics?
Cotter, P. D., Ross, R. P., & Hill, C. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro2937 · Cited by 1,793
Ford, A. C., Quigley, E. M. M., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Moayyedi, P. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.202 · Cited by 747
Didari, T. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i10.3072 · Cited by 356
Hungin, A. P. S., Mulligan, C., Pot, B., Whorwell, P., Agréus, L., Fracasso, P., Lionis, C., Mendive, J., Philippart de Foy, J.-M., Rubin, G., et al. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12460 · Cited by 212
Möndel, M., Schroeder, B. O., Zimmermann, K., Huber, H., Nuding, S., Beisner, J., Fellermann, K., Stange, E. F., & Wehkamp, J. (2009) · Mucosal Immunology · doi:10.1038/mi.2008.77 · Cited by 157
Enck, P., Zimmermann, K., Menke, G., Müller‐lissner, S., Martens, U., & Klosterhalfen, S. (2008) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2008.01156.x · Cited by 123 · cited 1×
“This resulted in an analysis where the 264 patients of Enck et al. 2008 and the 298 patients from Enck et al. 2009 were combined [35], ignoring the fact that in the latter trial Symbioflor was used while in the first ProSymbioflor had been applied (the bacterial lysate).”
MethodEnck, P., Zimmermann, K., Menke, G., & Klosterhalfen, S. (2009) · Zeitschrift für Gastroenterologie · doi:10.1055/s-2008-1027702 · Cited by 100
Escherichia coli Nissle 1917 (Mutaflor): New Insights into an Old Probiotic Bacterium
Jacobi, C. A., & Malfertheiner, P. (2011) · Digestive Diseases · doi:10.1159/000333307 · Cited by 95 · cited 1×
“The properties of that strain have been reviewed elsewhere [1], but here all peer-reviewed publications dealing”
BackgroundCharacterization of probiotic Escherichia coliisolates with a novel pan-genome microarray
Willenbrock, H., Hallin, P. F., Wassenaar, T. M., & Ussery, D. W. (2007) · Genome Biology · doi:10.1186/gb-2007-8-12-r267 · Cited by 94 · cited 2×
“A core genome of 3083 genes was identified that all four genotypes shared [11].”
BackgroundZschüttig, A., Zimmermann, K., Blom, J., Goesmann, A., Pöhlmann, C., & Gunzer, F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033351 · Cited by 81
Olfactomedin-4 is a glycoprotein secreted into mucus in active IBD
Gersemann, M., Becker, S., Nuding, S., Antoni, L., Ott, G., Fritz, P., Oue, N., Yasui, W., Wehkamp, J., & Stange, E. F. (2011) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2011.09.013 · Cited by 80
Irritable bowel syndrome in children: Pathogenesis, diagnosis and evidence-based treatment
Sandhu, B., & Paul, S. P. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i20.6013 · Cited by 80
Probiotics, prebiotics and the gastrointestinal tract in health and disease
Vitetta, L., Briskey, D. R., Alford, H., Hall, S., & Coulson, S. (2014) · Inflammopharmacology · doi:10.1007/s10787-014-0201-4 · Cited by 79
Inhibition of growth of Shiga toxin-producing Escherichia coli by nonpathogenic Escherichia coli
Reissbrodt, R., Hammes, W. P., dal Bello, F., Prager, R., Fruth, A., Hantke, K., Rakin, A., Starcic-Erjavec, M., & Williams, P. H. (2009) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2008.01405.x · Cited by 73
Mazurak, N., Broelz, E., Storr, M., & Enck, P. (2015) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm15071 · Cited by 71 · cited 3×
“They pointed out that over the years the heterogeneity in studies had increased instead of decreasing towards consensus and that few trials followed the rules and proper practice of randomised clinical trials (RCT) as outlined by the FDA, EMA, and the Rome group [36].”
BackgroundInfluentialBacteria Regulate Intestinal Epithelial Cell Differentiation Factors Both In Vitro and In Vivo
Becker, S., Oelschlaeger, T. A., Wullaert, A., Pasparakis, M., Wehkamp, J., Stange, E. F., & Gersemann, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055620 · Cited by 64
Visceral Pain and Gastrointestinal Microbiome
Chichlowski, M., & Rudolph, C. (2015) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm15025 · Cited by 63 · cited 2×
“complex interactions were reviewed by [37].”
Actual concept of "probiotics": Is it more functional to science or business?
Caselli, M. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i10.1527 · Cited by 59
Virulence genes in a probioticE. oliproduct with a recorded long history of safe use
Wassenaar, T. M., Zschüttig, A., Beimfohr, C., Geske, T., Auerbach, C., Cook, H., Zimmermann, K., & Gunzer, F. (2015) · European Journal of Microbiology and Immunology · doi:10.1556/eujmi-d-14-00039 · Cited by 45
Self-citationNon‐pathogenic commensal Escherichia coli bacteria can inhibit degranulation of mast cells
Magerl, M. A. K., Lammel, V., Siebenhaar, F., Zuberbier, T., Metz, M., & Maurer, M. (2008) · Experimental Dermatology · doi:10.1111/j.1600-0625.2008.00704.x · Cited by 44
Probiotic treatment of irritable bowel syndrome in children
Martens, U., Enck, P., & Zieseniß, E. (2010) · PubMed Central · doi:10.3205/000096 · Cited by 35
Discriminating bacteria from other atmospheric particles using femtosecond molecular dynamics
Courvoisier, F., Boutou, V., Guyon, L., Roth, M., RABITZ, H. A., & Wolf, J. (2006) · Journal of Photochemistry and Photobiology A Chemistry · doi:10.1016/j.jphotochem.2006.03.039 · Cited by 28
Diversity, transmission and persistence of Escherichia coli in a cohort of mothers and their infants
de Muinck, E. J., Øien, T., Storrø, O., Johnsen, R., Stenseth, N. C., Rønningen, K. S., & Rudi, K. (2011) · Environmental Microbiology Reports · doi:10.1111/j.1758-2229.2010.00231.x · Cited by 28 · cited 4×
“coli served as the model organism [17].”
BackgroundInfluentialSchulze, J., & Sonnenborn, U. (1995) · Infection · doi:10.1007/bf01793863 · Cited by 24
Wassenaar, T. M., & Gunzer, F. (2015) · Gut Pathogens · doi:10.1186/s13099-015-0062-4 · Cited by 21
Pöhlmann, C., Thomas, M., Förster, S., Brandt, M., Hartmann, M., Bleich, A., & Gunzer, F. (2012) · Bioengineered · doi:10.4161/bioe.22646 · Cited by 20
Zschüttig, A., Auerbach, C., Meltke, S., Eichhorn, C., Brandt, M., Blom, J., Goesmann, A., Jarek, M., Scharfe, M., Zimmermann, K., et al. (2015) · Genome Announcements · doi:10.1128/genomea.01330-14 · Cited by 16
Wassenaar, T. M., Beimfohr, C., Geske, T., & Zimmermann, K. (2014) · Beneficial Microbes · doi:10.3920/bm2013.0087 · Cited by 16
Self-citationIdentification of biological microparticles using ultrafast depletion spectroscopy
Courvoisier, F., Bonacina, L., Boutou, V., Guyon, L., Bonnet, C., Thuillier, B., Extermann, J., Roth, M., RABITZ, H. A., & Wolf, J. (2007) · Faraday Discussions · doi:10.1039/b615221j · Cited by 16
Escherichia coli as a probiotic?
Jansen, G. J., Wildeboer-Veloo, A. C. M., van der Waai, D., & Degener, E. (1998) · Infection · doi:10.1007/bf02962369 · Cited by 12
Mild gut inflammation modulates the proteome of intestinal E scherichia coli
Schumann, S., Alpert, C., Engst, W., Klopfleisch, R., Loh, G., Bleich, A., & Blaut, M. (2013) · Environmental Microbiology · doi:10.1111/1462-2920.12192 · Cited by 9
The story of live human intestinal bacteria administered orally as a remedy
Knothe, H. (1995) · Infection · doi:10.1007/bf01781196 · Cited by 6
Functional Characterization of Probiotic Pharmaceuticals by Quantitative Analysis of Gene Expression
Giese, T., Zimmermann, K., & Meuer, S. C. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1297125 · Cited by 6
Szikszai, T., Lasitschka, F., Giese, T., Greulich, M., Lee, Y.-S., Ilse, J., Schiessling, S., Leowardi, C., Al‐Saeedi, M., Winter, J., et al. (2015) · Journal of Immunological Methods · doi:10.1016/j.jim.2014.12.014 · Cited by 3
Svanborg, C. (1995) · Infection · doi:10.1007/bf01781214 · Cited by 2
["Control of symbiosis" or "microbiological therapy"--an immunological therapy principle?].
Heyll, U., & Wachauf, P. (1997) · PubMed · Cited by 1
Cited by
Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli
Pleguezuelos-Manzano, C., Puschhof, J., Rosendahl Huber, A., van Hoeck, A., Wood, H. M., Nomburg, J., Gurjao, C., Manders, F., Dalmasso, G., Stege, P. B., et al. (2020) · Nature · doi:10.1038/s41586-020-2080-8 · Cited by 1,208
Developing a new class of engineered live bacterial therapeutics to treat human diseases
Charbonneau, M. R., Isabella, V. M., Li, N., & Kurtz, C. B. (2020) · Nature Communications · doi:10.1038/s41467-020-15508-1 · Cited by 523
Postbiotics and paraprobiotics: From concepts to applications
Cuevas-González, P. F., Liceaga, A. M., & Aguilar-Toalá, J. E. (2020) · Food Research International · doi:10.1016/j.foodres.2020.109502 · Cited by 431
The Potential Impact of Probiotics on Human Health: An Update on Their Health-Promoting Properties
Maftei, N.-M., Raileanu, C. R., Balta, A. A., Ambrose, L., Boev, M., Marin, D. B., & Lisa, E. L. (2024) · Microorganisms · doi:10.3390/microorganisms12020234 · Cited by 381
“[77–79] The number of probiotics is measured in colony-forming units (CFUs), which indicates the number of viable cells—for example, 1 × 10 9 or 1 billion CFU and 1 × 10 10 or 10 billion CFU).”
MethodGut microbiota as a source of novel antimicrobials
Garcia-Gutierrez, E., Mayer, M. J., Cotter, P. D., & Narbad, A. (2019) · Gut Microbes · doi:10.1080/19490976.2018.1455790 · Cited by 292
“coli genotypes, and used for gastrointestinal disorder treatments, especially intestinal bowel syndrome (IBS).(136) Microcin S inhibits the adhesion of the enteropathogenic E.”
Metadata
- Authors
- Beimfohr, C.
- Affiliations
- Vermicon (Germany) (DE)
- Corresponding author
- Beimfohr, Claudia
- ORCID
- Beimfohr, Claudia
- Venue
- International Journal of Bacteriology
- Publisher
- Wiley
- Published
- 2016-11-22
- Volume
- 2016
- Pages
- 1-10
- ISSN
- 2314-596X (ISSN-L)
- 2356-6957
- PMC
- PMC5138452
- OpenAlex
- W2555723171
- Cited by
- 30
- References
- 38
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 4 · 2023: 1 · 2022: 2 · 2021: 7 · 2020: 4 · 2019: 2 · 2018: 2
- FWCI
- 0.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- International Journal of Bacteriology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Nursing › Nutrition and Dietetics › Infant Nutrition and Health
- Keywords
- probiotic Escherichia coli, probiotic activity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.